首页> 外国专利> 5.6 - disubstituierte (3 aminopyrazinoyl) - guanidinverbindungen and procedures for their production

5.6 - disubstituierte (3 aminopyrazinoyl) - guanidinverbindungen and procedures for their production

机译:5.6-双歧取代基(3氨基吡嗪酰基)-胍基双胍及其生产程序

摘要

The invention comprises compounds of the general formula I FORM:1066855/C2/1 in which X is a hydrogen or halogen atom, a trihalomethyl, C1- 6 alkyl, C3 to C6 cycloalkyl, mononuclear aryl, anilino, C1- 5 alkylthio, C1- 5-alkylsulphonyl, phenyl-substituted C1- 5 alkylthio or phenyl-substituted C1- 5 alkylsulphonyl; Y is a hydrogen or halogen atom or a hydroxyl, mercapto, C1- 5 alkoxy, C1- 5 alkylthio, C1- 6 alkyl, C3- 6 cycloalkyl, mononuclear aryl or 4-methyl-1-piperazinyl group or an amino group of the formula -NRR1, wherein R is a hydrogen atom or an amino, amidino, C3- 6 cycloalkyl, C1- 6 alkyl, hydroxy-substituted C1- 6 alkyl, halogen-substituted C1- 6 alkyl, (C3- 6 cycloalkyl)-(C1- 5 alkyl), phenyl-substituted C1- 5 alkyl, (C1- 5 alkyl) phen-(C1- 5 alkyl), halophenyl-substituted C1- 5 alkyl, furyl-substituted C1- 5 alkyl, pyridyl-substituted C1- 5 alkyl, C1- 5 alkylamino (C1- 5 alkyl), C2- 6 alkenyl, b -aminoethyl, phenyl, halophenyl or (C1- 5 alkyl) phenyl radical and R1 is a hydrogen atom or a C1- 6 alkyl or C2- 6 alkenyl radical or R and R1 are joined to form a C2- 6 alkylene radical, but with the proviso that Y is not hydrogen when X is hydrogen, halogen or trihalomethyl; or X and Y together form a tetramethylene, 1,3-butadienylene or 2-chloro-1,3-butadienylene radical; Z is an amino, monosubstituted amino, disubstituted amino, or heterocyclic amino radical; R2 is a hydrogen atom or a C1- 6 alkyl radical; each of R3 and R4 is a hydrogen atom or a C1- 6 alkyl, hydroxy-substituted C1- 6 alkyl, phenyl-substituted C1- 5 alkyl, halophenyl-substituted C1- 5 alkyl, (C1- 5 alkyl) phen-(C1- 5 alkyl), (C1- 5 alkoxyphenyl) substituted C1- 5 alkyl, naphthyl-substituted C1- 5 alkyl, (octahydro-1-azocinyl)-substituted C1- 5 alkyl, pyridyl-substituted C1- 5 alkyl, or phenyl radical; or R3 and R4, together with the nitrogen atom to which they are attached, represent a 1-pyrrolidinyl, piperidino, morpholino, or 4-(C1- 4 alkyl)-piperazinyl group and pharmaceutically acceptable salts thereof. These compounds may be prepared by the following methods: (1) reacting a substituted pyrazinoic acid ester of the Formula II FORM:1066855/C2/2 wherein R* is a C1-alkyl radical with a guanidine of formula FORM:1066855/C2/3 to produce a compound of Formula I; (2) reacting a (3-amino-5,6-dichloropyrazinoyl) guanidine of the Formula III FORM:1066855/C2/4 with an amine of formula RR1NH to produce a compound of Formula IV FORM:1066855/C2/5 (3) reacting a C1-alkyl ester of a 3-amino-5,6-dihalopyrazinoic acid with a saturated alcohol or phenol to produce the corresponding C1-alkyl ester of 3-amino-5-alkoxy- (or aryloxy-)-6-halopyrazinoic acid and reacting the latter with a guanidine of the formula FORM:1066855/C2/6 to produce a compound of Formula V FORM:1066855/C2/7 (4) acylating a compound of Formula VI FORM:1066855/C2/8 with an acid anhydride of the formula (R5CO)2O to produce a 2-alkyl-4H-pyrazino-[2,3-d][1,3]-oxazin-4-one of the Formula VII FORM:1066855/C2/9 and reacting the latter with a guanidine of formula FORM:1066855/C2/100 to produce a compound of the Formula VIII FORM:1066855/C2/111 the N-acyl group of which may be removed by hydrolysis if desired, and (5) catalytic hydrogenolysis of a compound of the Formula IX FORM:1066855/C2/122 where R11 is an alkyl radical, to replace the chlorine atom by hydrogen, brominating the resulting 6-unsubstituted compound to introduce a 6-bromine atom, and reacting the latter with a guanidine of the formula FORM:1066855/C2/133 to produce a compound of the Formula X FORM:1066855/C2/144 The intermediate 3-aminopyrazinoic acid esters may be produced by the methods represented by the following reaction schemes: FORM:1066855/C2/155 FORM:1066855/C2/166 FORM:1066855/C2/177 FORM:1066855/C2/188 FORM:1066855/C2/199 where R in steps (b) and (c) represents a C1- 5 alkyl radical; FORM:1066855/C2/200 FORM:1066855/C2/211 The compounds of Formula VI may be prepared by hydrolysis of the corresponding esters or amides or, for those compounds having a 6-RS or 6-RSO2 group, the method represented by the reaction scheme FORM:1066855/C2/222 where R is a C1 alkyl or a phenyl-substituted C1 alkyl radical. The compounds of Formula III may be prepared by reacting a pyrazinoic acid ester of formula FORM:1066855/C2/233 where R11 is an alkyl radical, with a guanidine of the formula FORM:1066855/C2/244ALSO:Pyrazinoylguanidines of the general formula I FORM:1066855/A5-A6/1 in which X is a hydrogen a halogen atom, a trihalo-methyl, C1-6 alkyl, C3-6 cycloalkyl, mononuclear aryl, anilino, C1-5 alkylthio, C1-5 alkylsulphonyl, phenyl-substituted C1-5 alkylthio, or phenyl-substituted C1-5 alkylsulphonyl; 7 is a hydrogen or halogen atom or a hydroxyl, mercapto, C1-5 alkoxy, C1-5 alkylthio, C1-6 alkyl, C3-6 cycloalkyl, mononuclear aryl or 4-methyl-1-piperazinyl group or an amino group of the formula -NRR1, where R is a hydrogen atom or an amino, amidino, C3-6 cycloalkyl, C1-6 alkyl, hydroxy-substituted C1-6 alkyl,, halogen-substituted C1-6 alkyl, (C3-6 cycloalkyl)-(C1-5 alkyl), phenyl-substituted C1-5 alkyl, (C1-5 alkyl) phen (C1-5 alkyl), halophenyl substituted C1-5 alkyl, furyl-substituted C1-5 alkyl, pyridyl substituted C1-5 alkyl, C1-5 alkylamino (C1-5 alkyl), C2-6 alkenyl, b -aminoethyl, phenyl, halophenyl or (C1-5 alkyl) phenyl radical and R1 is a hydrogen atom or a C1-6 alkyl or C2-6 alkenyl radical or R and R1 are joined to form a C2-6 alkylene radical, but with the proviso that 7 is not hydrogen when X is hydrogen, halogen or trihalomethyl; or X and Y together form a tetramethylene, 1,3-butadienylene or 2-chloro-1,3-butadienylene radical; Z is an amino, mono-substituted amino, disubstituted amino or heterocyclic amino radical; R2 is a hydrogen atom or a C1-6 alkyl radical; each of R3 and R4 is a hydrogen atom or a C1-6 alkyl, hydroxy-substituted C1-6 alkyl, phenyl-substituted C1-5 alkyl, halophenyl-substituted C1-5 alkyl, (C1-5 alkyl) phen (C1-5 alkyl), (C1-5 alkoxyphenyl) substituted C1-5 alkyl, naphthyl-substituted C1-5 alkyl, (octahydro-1-azocinyl)-substituted C1-5 alkyl, pyridyl-substituted C1-5 alkyl, or phenyl radical; or R3 and R4, together with the nitrogen atom to which they are attached, represent a 1-pyrrolidinyl, piperidino, morpholino, or 4-(C1-4 alkyl)-piperazinyl group and pharmaceutically acceptable salts thereof are employed as duiretic and/or saluretic agents in, for example, pills, tablets, capsules, elixirs, injectable preparations. Other therapeutic agents may be present in the pharmaceutical compositions and when said known therapeutic agents administered alone enhance the elimination of potassium and sodium ions the co-administration of the guaridine of the formula I. Specified known diuretics employed in said pharmaceutical compositions are hydrochlorothiazide; 4sv-methyl-6-chloro-spiro-[2H-1,2,4-benzothiadiazide-3(4H) -1sv-cyclohexane] - 7 - sulphonamide-1,1-dioxide; trichloromethiazide; cyclopenthiazide; acetazolamide; dichlorophenamide; chlorthalidone; chlormerodrin; chlorazinil; or spironolactone.
机译:本发明包含通式I 的化合物,其中X是氢或卤素原子,三卤代甲基,C1-6烷基,C3至C6环烷基,单核芳基,苯胺基,C1-5烷硫基,C 1-5烷基磺酰基,苯基取代的C 1-5烷硫基或苯基取代的C 1-5烷基磺酰基; Y是氢或卤素原子或羟基,巯基,C1-5烷氧基,C1-5烷硫基,C1-6烷基,C-3-6环烷基,单核芳基或4-甲基-1-哌嗪基或氨基的氨基式-NRR1,其中R是氢原子或氨基,mid基,C3-6环烷基,C1-6烷基,羟基取代的C1-6烷基,卤素取代的C1-6烷基,(C3-6环烷基)-( C1-5烷基),苯基取代的C1-5烷基,(C1-5烷基)phen-(C1-5烷基),卤代苯基取代的C1-5烷基,呋喃基取代的C1-5烷基,吡啶基取代的C1- 5个烷基,C 1-5烷基氨基(C 1-5烷基),C 2-6烯基,b-氨基乙基,苯基,卤代苯基或(C 1-5烷基)苯基,并且R 1是氢原子或C 1-6烷基或C 2- 6个烯基或R和R 1连接形成C 2-6亚烷基,但条件是当X是氢,卤素或三卤代甲基时,Y不是氢。 X和Y一起形成四亚甲基,1,3-丁二烯基或2-氯-1,3-丁二烯基; Z为氨基,单取代氨基,二取代氨基或杂环氨基; R 2为氢原子或碳数1〜6的烷基。 R 3和R 4各自为氢原子或C 1-6烷基,羟基取代的C 1-6烷基,苯基取代的C 1-5烷基,卤代苯基取代的C 1-5烷基,(C 1-5烷基)phen-(C1 -5个烷基),(C1-5烷氧基苯基)取代的C1-5烷基,萘基取代的C1-5烷基,(八氢-1-偶氮基)取代的C1-5烷基,吡啶基取代的C1-5烷基或苯基; R 3和R 4以及与它们相连的氮原子一起代表1-吡咯烷基,哌啶子基,吗啉代或4-(C1-4烷基)-哌嗪基及其药学上可接受的盐。这些化合物可以通过以下方法制备:(1)使其中R *为C1-烷基的式II的取代的吡嗪酸酯与式产生式I的化合物; (2)使式III 的(3-氨基-5,6-二氯吡嗪酰基)胍与式RR1NH的胺反应以生成式IV化合物(3)使3-氨基-5,6-二卤代吡嗪酸的C1-烷基酯与饱和醇或苯酚反应,生成相应的3-氨基-5-烷氧基-(或芳氧基- )-6-卤代吡嗪酸并使后者与式的胍反应生成式V的化合物(4)酰化式VI的化合物与式(R5CO)2O的酸酐制得2-烷基-4H-吡嗪并-[2,3-d] [1,3]-恶嗪-4-酮式VII 并使后者与式的胍反应以生成式VIII化合物如果需要,可通过水解除去其酰基,以及(5)式IX的化合物的催化氢解:1066855 / C2 / 122>其中R11为烷基,以氢取代氯原子,溴化所得的6-未取代的化合物以引入6-溴原子,并使后者与下式的胍反应: 1066855 / C2 / 133>制备式X化合物中间体3-氨基吡嗪酸酯可以通过以下反应流程代表的方法制备: 其中,步骤(b)和(c)中的R表示C1-5烷基; 可以通过水解相应的酯或酰胺来制备式VI的化合物,或者对于具有6-RS或6-RSO 2基团的那些化合物,可以制备式VI的化合物。由反应方案表示的方法,其中R为C 1烷基或苯基取代的C 1烷基。式III的化合物可通过使式的吡嗪酸酯(其中R11为烷基)与式的胍反应而制备:ALSO:吡嗪基胍通式I的化合物其中X是氢,卤素原子,三卤代甲基,C1-6烷基,C3-6环烷基,单核芳基,苯胺基,C1-5烷硫基,C 1-5烷基磺酰基,苯基取代的C 1-5烷硫基或苯基取代的C 1-5烷基磺酰基; 7是氢或卤素原子或羟基,巯基,C 1-5烷氧基,C 1-5烷硫基,C 1-6烷基,C 3-6环烷基,单核芳基或4-甲基-1-哌嗪基或氨基的式-NRR1,其中R为氢原子或氨基,mid基,C3-6环烷基,C 1-6烷基,羟基取代的C 1-6烷基,卤素取代的C 1-6烷基,(C 3-6环烷基)-(C 1-5烷基),苯基取代的C 1-5烷基,(C 1-5烷基) )phen(C1-5烷基),卤代苯基取代的C1-5烷基,呋喃基取代的C1-5烷基,吡啶基取代的C1-5烷基,C1-5烷基氨基(C1-5烷基),C2-6链烯基,β-氨基乙基,苯基,卤代苯基或(C1-5烷基)苯基和R1为氢原子或C1-6烷基或C2-6烯基或R和R1连接形成C2-6亚烷基,但附带条件当X是氢,卤素或三卤甲基时,7不是氢; X和Y一起形成四亚甲基,1,3-丁二烯基或2-氯-1,3-丁二烯基; Z为氨基,单取代的氨基,二取代的氨基或杂环氨基; R2是氢原子或C1-6烷基。 R 3和R 4各自为氢原子或C 1-6烷基,羟基取代的C 1-6烷基,苯基取代的C 1-5烷基,卤代苯基取代的C 1-5烷基,(C 1-5烷基)phen(C1- 5烷基),(C 1-5烷氧基苯基)取代的C 1-5烷基,萘基取代的C 1-5烷基,(八氢-1-偶氮基)取代的C 1-5烷基,吡啶基取代的C 1-5烷基或苯基。或R 3和R 4与它们所连接的氮原子一起代表1-吡咯烷基,哌啶子基,吗啉代或4-(C 1-4烷基)-哌嗪基,并且其药学上可接受的盐用作Duiretic和/或药,例如丸剂,片剂,胶囊剂,preparation剂,注射剂。药物组合物中可存在其他治疗剂,并且当单独施用所述已知治疗剂可增强钾和钠离子的消除时,式I的瓜尔啶的共同施用。在所述药物组合物中使用的已知的利尿剂为氢氯噻嗪; 4 sv-甲基-6-氯-螺-[2H-1,2,4-苯并噻二叠氮-3(4H)-1 sv-环己烷] -7-磺酰胺-1,1-二氧化物;三氯甲叠氮;环戊噻嗪乙酰唑胺;二氯苯甲酰胺氯噻酮;氯merodrin;氯嗪腈或螺内酯。

著录项

  • 公开/公告号DE000001470053A

    专利类型

  • 公开/公告日1969-06-26

    原文格式PDF

  • 申请/专利权人 MERCK & CO INC;

    申请/专利号DE1470053A

  • 发明设计人 JUN EDWARD GRAGOE;

    申请日1963-10-28

  • 分类号C07D51/76;

  • 国家 DE

  • 入库时间 2022-08-23 12:17:59

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号